Search

Your search keyword '"Encinas M"' showing total 688 results
Start Over Author "Encinas M"
688 results on '"Encinas M"'

3. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

Author

Luna, A., Pérez-Lamas, L., Boque, C., Giraldo, P., Xicoy, B., Ruiz Nuño, C., Vega, M. Moreno, Alvarez-Larrán, A., Salamanca, A., García-Noblejas, A., Vall-Llovera, F., Villalon, L., De las Heras, N., Ramila, E., Pérez-Encinas, M., Cuevas, B., Perez-Lopez, R., Sanchez-Guijo, F., Jiménez-Velasco, A., Lakhwani, S., Casado, L. Felipe, Rosell, A., Escola, A., Fernández, M. J., Garcia-Hernandez, C., Cervero, C., Mora, E., Sagüés, M., Suarez-Varela, S., Vélez, P., Carrascosa Mastell, P., Bitaube, R. F., Serrano, L., Cortes, M., Vera Goñi, J.A, Steegmann, J. L., de Soria, V. Gomez Garcia, Alonso-Dominguez, J. M., Araujo, M. Colorado, Coll, A. Paz, Hernandez-Boluda, J.C, and García-Gutiérrez, V.

Published
2022
Full Text
View/download PDF

8. Outcomes of an enhanced recovery after radical cystectomy program in a prospective multicenter study: compliance and key components for success

Author

Llorente, C., Guijarro, A., Hernández, V., Fernández-Conejo, G., Passas, J., Aguilar, L., Tejido, A., Hernández, C., Moralejo, M., Subirá, D., González-Enguita, C., Husillos, A., Ortiz, F., Sánchez-Chapado, M., Carballido, J., Castillón, I., Mateo, E., Romero, I., del Álamo, J. Fernández, Llanes, L., Blázquez, C., Sánchez-Encinas, M., Borrego, J., Téllez, M., Díez, L., Carrero, V. M., Pérez-Fernández, E., Fuentes-Ramirez, L., and Del Valle, S. García

Published
2020
Full Text
View/download PDF

9. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Author

Rojas, F., Longoni, H., Milone, G., Fernández, I., Conciencia, Clínica, Ramirez, R., Canepa, C., Saba, S., Balladares, G., Ventiurini, C., Mariano, R., Negri, P., Prates, M.V., Milone, J., Fazio, P., Gelemur, M., Ciarlo, S., Bezares, F., López, L., García, J. J, Giunta, M., Kruss, M., Lafalse, D., Marquesoni, E., Casale, M.F., Gimenez, A., Brulc, E.B., Perusini, M.A., Palmer, L., Correa, M.E., Jaramillo, F.J., Rosales, J., Sossa, C., Herrera, J.C., Arango, M., Holojda, J., Golos, A., Ejduk, A., Ochrem, B., Małgorzata, G., Waszczuk-Gajda, A., Drozd-Sokolowska, J., Czemerska, M., Paluszewska, M., Zarzycka, E., Masternak, A., Hawrylecka, Dr., Podhoreka, M., Giannopoulos, K., Gromek, T., Oleksiuk, J., Armatys, bA., Helbig, G., Sobas, M., Szczepaniak, A., Rzenno, E., Rodzaj, M., Piatkowska-Jakubas, B., Skret, A., Pluta, A., Barańska, E., Vasconcelos, G., Brioso, J., Nunes, A., Bogalho, I., Espadana, A., Coucelo, M., Marini, S., Azevedo, J., Crisostomo, A.I., Ribeiro, L., Pereira, V., Botelho, A., Mariz, J.M., Guimaraes, J.E., Aguiar, E., Coutinho, J., Noriega, V., García, L., Varela, C., Debén, G., González, M.R., Encinas, M., Bendaña, A., González, S., Bello, J.L., Albors, M., Algarra, L., Romero, J.R., Bermon, J.S., Varo, M.J., López, V., López, E., Mora, C., Amorós, C., Romero, A., Jaramillo, A., Valdez, N., Molina, I., Fernández, A., Sánchez, B., García, A., Castaño, V., López, T., Bernabeu, J., Sánchez, M.J., Fernández, C., Gil, C., Botella, C., Fernández, P., Pacheco, M., Tarín, F., Verdú, J.J., García, M.J., Mellado, A., García, M.C., González, J., Castillo, T., Colado, E., Alonso, S., Recio, I., Cabezudo, M., Davila, J., Rodríguez, M.J., Barez, A., Díaz, B., Prieto, J., Arnan, M., Marín, C., Mansilla, M., Balaberdi, A., Amutio, M.E., del Orbe, R.A., Ancin, I., Ruíz, J.C., Olivalres, M., Gómez, C., gonzález, I., Celis, M., Atutxa, K., Carrascosa, T., Artola, T., Lizuain, M., Rodriguez, J .I., Arce, O., Márquez, J.A., Atuch, J., Marco de Lucas, F., Díez, Z., Dávila, B., Cantalejo, R., Díaz, M., Labrador, J., Serra, F., Hermida, G., Díaz, F.J., de Vicente, P., Álvarez, R., Alonso, C., Bergua, J.M., Ugalde, N., Pardal, E., Saldaña, R., Rodríguez, F., Martín, E., Hermosín, L., Garrastazul, M.P., Marchante, I., Raposo, J.A., Capote, F.J., Colorado, M., Batlle, A., Yañez, L., García, S., González, P., Ocio, E.M., Briz, M., Bermúdez, A., Jiménez, C., Beltrán, S., Montagud, M., Castillo, I., García, R., Gascón, A., Clavel, J., Lancharro, A., Lnares, L., Herráez, M.M., Milena, A., Romero, M.J., Hernández, B., Calle, C., Benegas, R., Bolívar, Dr., Serrano, J., Dorado, F.J., Sánchez, J., Martínez, M.C., Cerveró, C.J., Busto, M.J., Bernal, M., Moratalla, L., Mesa, Z., Jurado, M., De Miguel, D., Santos, A.B., Arbeteta, J., Pérez, E., Caminos, N., Uresandi, N., Argoitiaituart, N., Swen, J., Uranga, A., Olazaba, I., Gainza, E., Romero, P., Gil, E., Palma, A.J., Gómez, K.G., Solé, M., Rodríguez, J.N., Murillo, I.M., Marco, J., Serena, J., Marco, V., Perella, M., Costilla, L., López, J.A., Baena, A., Almagro, P., Hermosilla, M., Esteban, A., Campeny, B.A., Nájera, M.J., Herrra, P., Fernández, R., González, J.D., Torres, L., Jiménez, S., Gómez, M.T., Bilbao, C., Rodríguez, C., Hong, A., Ramos de Laón, Y., Afonso, V., Ramos, F., Fuertes, M., de Cabo, E., Aguilera, C., Megido, M., García, T., Lavilla, E., Varela, M., Ferrero, S., Arias, J., Vizcaya, L., Roldán, A., Vilches, A., Penalva, M.J., Vázquez, J., Calderón, M.T., Matilla, A., Serí, C., Otero, M.J., García, N., Sandoval, E., Franco, C., Flores, R., Bravo, P., López, A., López, J.L., Blas, C., Díez, A., Alonso, J.M., Soto, C., Arenas, A., García, J., Martín, Y., Villafuerte, P.S., Magro, E., Bautista, G., De Laiglesia, A., Rodríguez, G., Solán, L., Chicano, M., Balsalobre, P., Monsalvo, S., Font, P., Carbonell, D., Martínez, C., Humala, K., Kerguelen, A.E., Hernández, D., Gasior, M., Gómez, P., Sánchez, I., Redondo, S., Llorente, L., Bengochea, M., Pérez, J., Sebrango, A., M. santero, Morales, A., Figuera, A., Villafuerte, P., Alegre, A., Fernández, E., Alonso, A., Martínez, M.P., Martínez, J., Cedena, M.T., Moreno, L., De la Fuente, A., García, D., Chamorro, C., Pradillo, V., Martí, E., Sánchez, J.M., Delgado, I., Rosado, B., Velasco, A., Miranda, C., Salvatierra, G., Foncillas, M., Hernández, J.A., Escolano, C., Benabente, C., Martínez, R., Polo, M., Anguita, E., Riaza, R., Amores, G., Requena, M.J., Javier, F., Villaloón, L., Aláez, C., Nistal, S., Navas, B., Andreu, M.A., Herrera, P., López, J., García, M., Moreno, M.J., Queipo, M.P., Hernández, A., Barrios, M., Heiniger, A., Jiménez, A., Contento, A., López, F., Alcalá, M., Lorente, S., González, M., Morales, E.M., Gutierrez, J., Serna, M.J., Beltrán, V., Romera, M., Berenguer, M., MArtínez, A., Tejedor, A., Amigo, M.L., Ortuño, F., Jerez, A., López, O., Moraleda, J.M., Rosique, P., Gómez, J., Garay, M.C., Cerezuela, P., MArtínez, A.B., González, A., Ibáñez, J., Alfaro, M.J., Mateos, M., Goñi, M.A., Araiz, M.A., Gorosquieta, A., Zudaire, M., Viguria, M., Zabala, A., Alvarellos, M., Quispe, I., Sánchez, M.P., Hurtado, G., Pérez, M., Burguete, Y., Areizaga, N., Galicia, T., Rifón, J., Alfonso, A., Prósper, F., Marcos, M., Tamariz, L.E., Riego, V., Manubens, A., Larrayoz, M.J., Calasanz, M.J., Mañú, A., Paiva, B., Vázquez, I., Burgos, L., Pereiro, M., Rodríguez, M., Pastoriza, M.C., Mendez, J.A., Sastre, J.L., Iglesias, M., Ulibarrena, C., Campoy, F., Jaimes, D., Albarrán, B., Solano, J., Silvestre, A., Albo, C., Suarez, S., Loureiro, C., Figueroa, I., Fernández, M.A., Martínez, A., Poderós, C., Vazquez, J., Iglesias, L., Nieto, A., Torrado, T., Martínez, A.M., Amador, M.L., Oubiña, P., Feijó, E., Dios, A., Loyola, I., Roreno, R., Simiele, A., Álvarez, L., Turcu, V., Vidriales, B., Avendaño, A., Chillón, C., González, V., Govantes, J.V., Rubio, S., Tapia, M., Olivier, C., Queizán, J.A., Pérez, O., Vera, J.A., Muñoz, C., rodriguez, A., González, N., Pérez, J.A., Soria, E., I.Espigado, Falantes, J., Montero, I., García, P., Rodríguez, E., Carrillo, E., Caballero, T., García, C., Couto, C., Simón, I., Gómez, M., Aguilar, C., González, B.J., Lakhwani, S., Bienert, A., González, B., Cabello, A., Oliva, A.Y., González, H., Sancho, L., Paricio, M., Perdiguer, L., Solano, F., Lerma, A., Martínez, M.D., Gómez, M.I., Yeguas, A., Montesinos, P., Barragán, E., Sargas, C., Amigo, R., Martinez, D., Boluda, B., Rodríguez, R., Acuña, E., Cano, I., Escrivá, A., Pedreño, M., Navalón, A., Orts, M., Sayas, M.J., Fernández, M.J., Juan, M.L., Gómez, E., Gimeno, M., Donato, E., Cejalvo, M., Tormo, M., Calabuig, M., Navarro, B., Martin, I., Villamont, E., Miralles, A., Lluch, R., Moragues, M., Ruiz, M.A., Benet, C., Valero, M., Linares, M., Collado, R., Orero, M., Ibañez, P., Lis, M.J., Pérez, P.L., Roig, M., López, M., Mena, A.V., Picón, I., Cánovas, V., Palacios, A., Cuello, R., Borrego, J., burgois, M., Cantalapiedra, A., Norberto, O., Angomas, E., Cidoncha, B., Cuevas, L., Robles, D., Mendiazabal, A., Oiartzabal, I., Guinea de Castro, J.M., Montes, C., Carrasco, V., Pérez, A., Moneva, J.J., Olave, M., Bonafonte, E., Mayor, L., Azaceta, G., Palomera, L., Malo, M., Escobar, M.J., Grasa, J.M., De Rueda, B., Aulés, A., Salvador, C., Ansó, V., Iborra, A., Delagado, P., Rubio, A., Stevenazzi, M., Alpire, I., Irigoin, V., Díaz, L., Guillermo, C., Guadagna, R., Grille, S., Oliver, C., Boada, M., Vales, V., Prado, A.I., De los Santos, A.P., Simoes, Catia, Gonzalez, Carmen, Vergez, François, Sarry, Audrey, Bertoli, Sarah, Ariceta, Beñat, Martínez-Cuadrón, David, Bergua, Juan-Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, Lopez-Lorenzo, Jose-Luis, Vidriales, Maria-Belen, Chillon, Carmen, Labrador, Jorge, Falantes, Jose-Francisco, Sayas, María-José, Ayala, Rosa, Martinez-Lopez, Joaquin, Villar, Sara, Calasanz, Maria-Jose, Prosper, Felipe, San-Miguel, Jesús F., Sanz, Miguel Á., Récher, Christian, Paiva, Bruno, and Montesinos, Pau

Published
2024
Full Text
View/download PDF

18. Categories First.

Author

García-Encinas, M. J.

Subjects
*JOB creation, *FRICTION, *THEORY of knowledge, *METAPHYSICS, *A priori, *INTUITION
Abstract

Vaidya and Wallner [2021] claim that most relevant theories in recent epistemology of modality, that is, Conceivability-Theory, Counterfactual-Theory, and Deduction-Theory, face what they name "the problem of modal epistemic friction", in a nutshell, the need to add some relevant information about the nature of the world that is not provided by the theories as such. Their proposal is that essences supply the needed information. In this paper I will agree with Vaidya and Waller's detection of the problem of modal epistemic friction, but I will importantly disagree with their solution in terms of a metaphysics and epistemology of essences. I will argue that knowledge of essence is neither necessary nor sufficient for metaphysical modal knowledge and claim instead that modal knowledge is firstly grounded in the categories that conform the facts of reality. Categorial knowledge does the job of creating the friction needed in all cases of modal metaphysical knowledge.Moreover, given the structural character of metaphysical categories, intuition is the basic proper form of modal knowledge. In fact, I will contend that intuition is the source of a priori knowledge invoked in Kripkean schemas for a posteriori modal truths. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. P1032: REAL-LIFE VALIDATION OF MIPSS70: A RETROSPECTIVE MULTICENTER AND NGS ANALYSIS FROM THE GEMFIN DATABASE

Author

Hernández-Sánchez, A., primary, Villaverde-Ramiro, Á., additional, Álvarez-Larrán, A., additional, Arellano-Rodrigo, E., additional, Pérez Encinas, M., additional, Ferrer Marín, F., additional, Such, E., additional, Carreño Gómez-Tarragona, G., additional, de las Heras Rodríguez, N., additional, Durán Pastor, M. A., additional, Mata Vázquez, M. I., additional, Fox, L., additional, Raya Sánchez, J. M., additional, Magro Mazo, E., additional, Gómez Casares, M. T., additional, Ramírez Sánchez, M. J., additional, Xicoy Cirici, B., additional, Ramírez Páyer, Á., additional, Fernández Llavador, M. J., additional, Martín López, A. Á., additional, Mosquera Orgueira, A., additional, Martínez Elicegui, J., additional, Garrote, M., additional, Bellosillo, B., additional, González, T., additional, Hernández-Rivas, J., additional, and Hernández Boluda, J. C., additional

Published
2022
Full Text
View/download PDF

24. P432: RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA: EXTERNAL VALIDATION OF THE STELLAE-123 GENE EXPRESSION MODEL AND COMPARISON WITH CURRENT PROGNOSTIC SCORES

Author

Mosquera Orgueira, A., primary, Peleteiro Raindo, A., additional, Diaz Arias, J. A., additional, Cid Lopez, M., additional, Abal Garcia, R., additional, Antelo Rodriguez, B., additional, Gonzalez Perez, M. S., additional, Vallejo Llamas, J. C., additional, and Perez Encinas, M. M., additional

Published
2022
Full Text
View/download PDF

25. P508: REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY.

Author

Bernal, T., primary, Rad, G., additional, de Laiglesia, A., additional, Benavente, C., additional, Garcia Noblejas, A., additional, Garcia Belmonte, D., additional, Riaza, R., additional, Salamero, O., additional, Foncillas, A., additional, Roldán, A., additional, Noriega Concepcion, V., additional, Perez de Oteyza, J., additional, Bergua Burgues, J. M., additional, Lorente de Uña, S., additional, de la Fuente Burguera, A., additional, Garcia Perez, M. J., additional, Lopez Lorenzo, J. L., additional, Martinez, P., additional, Alaez, C., additional, Callejas, M., additional, Martinez Chamorro, C., additional, Rifon Roca, J., additional, Amador Barciela, L., additional, Lopez, M., additional, Gomez Correcha, K., additional, Lavilla Rubiera, E., additional, Amigo, M. L., additional, Vall-Llovera, F., additional, Garrido, A., additional, Garcia Fortes, M., additional, de Miguel Llorente, D., additional, Aules Leonardo, A., additional, Cervero, C., additional, Coll Jorda, R., additional, Perez Encinas, M., additional, Polo Zarzuela, M., additional, Martinez Cuadron, D., additional, and Montesinos, P., additional

Published
2022
Full Text
View/download PDF

26. P1001: DNMT3A/TET2/ASXL1 MUTATIONS DETERMINE THROMBOTIC RISK IN POLYCYTHAEMIA VERA

Author

Segura Diaz, A., primary, Stuckey, R., additional, Florido Ortega, Y., additional, Sobas, M., additional, Álvarez Larrán, A., additional, Ferrer-Marín, F., additional, Pérez Encinas, M., additional, Carreño, G., additional, Fox, M., additional, Tazón Vega, B., additional, Cuevas, B., additional, López Rodriguez, J., additional, Farías Sánchez, N., additional, Bilbao Sieyro, C., additional, and Gómez Casares, M., additional

Published
2022
Full Text
View/download PDF

33. Correction to: Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

Author

Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Vélez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martínez C, Pérez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, and Alvarez-Larran A

Published
2022

34. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

Author

Hernandez-Boluda, JC, Pastor-Galan, I, Arellano-Rodrigo, E, Raya, JM, Perez-Encinas, M, Ayala, R, Ferrer-Marin, F, Velez, P, Mora, E, Fox, ML, Hernandez-Rivas, JM, Xicoy, B, Mata-Vazquez, MI, Garcia-Fortes, M, Perez-Lopez, R, Angona, A, Cuevas, B, Senin, A, Ramirez, MJ, Ramirez-Payer, A, Gomez-Casares, MT, Martinez-Valverde, C, Magro, E, Steegmann, JL, Duran, MA, Garcia-Hernandez, C, Gasior, M, de Villambrosia, SG, Alvarez-Larran, A, and Pereira, A

Subjects
treatment, Primary Myelofibrosis, Risk Factors, Humans, Thrombosis, Hemorrhage, myelofibrosis, Hematology, Registries, bleeding, thrombosis, Thrombocythemia, Essential
Abstract

Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in 1613 patients from the Spanish Myelofibrosis Registry. Over a total of 6981 patient-years at risk, 6.4% of the study population had at least one thrombotic event after MF diagnosis, amounting to an incidence rate of 1.65 per 100 patient-years. Prior history of thrombosis, the JAK2 mutation, and the intermediate-2/high-risk International Prognostic Scoring System (IPSS) categories conferred an increased thrombotic risk after adjustment for the risk-modifying effect of anti-thrombotic and cytoreductive treatments. History of thrombosis and the JAK2 mutation allowed us to pinpoint a group of patients at higher risk of early thrombosis. No decreased incidence of thrombosis was observed while patients were on anti-thrombotic or cytoreductive treatment. An increased risk of venous thrombosis was found during treatment with immunomodulatory agents. A total of 5.3% of patients had at least one episode of major bleeding, resulting in an incidence rate of 1.5 events per 100 patient-years. Patients in the intermediate-2/high-risk IPSS categories treated with anti-coagulants had an almost sevenfold increased risk of major bleeding. These findings should prove useful for guiding decision-making in clinical practice.

Published
2022

36. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Author

Labrador, Jorge, Luno, Elisa, Vellenga, Edo, Brunet, Salut, Gonzalez-Campose, Jose, Chillon, Maria C., Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, Gonzalez-Sanmiguel, Jose D., Gil, Cristina, Tormo, M., Salamero, Olga, Manso, Felix, Fernandez, Isolda, de laSerna, Javier, Moreno, Maria-Jose, Perez-Encinas, M., Krsnik, Isabel, Ribera, Josep-Maria, Cervera, Jose, Calasanz, Maria J., Boluda, Blanca, Sobas, Marta, Lowenberg, Bob, Sanz, Miguel A., Montesinos, Pau, Palmer, L., Fernandez, Ciarlo, S., Bezares, F., Rojas, F., Longoni, H., Gelemur, M., Fazio, P., Canepa, C., Saba, S., Balladares, G., Negri, P., Giunta, M., Milone, J., Prates, M., Lafalse, D., Sossa, C., Jaramillo, F., Mayer, J., Ramos, F., Martinez, J., de Groot, M. R., Schouten, H. C., Hematology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Hematologie (9)

Subjects
Male, Cancer Research, complex karyotype, ANTHRACYCLINE MONOCHEMOTHERAPY, medicine.medical_treatment, Abnormal Karyotype, chemotherapy, Gastroenterology, Leukocyte Count, 0302 clinical medicine, Leukemia, Promyelocytic, Acute, Recurrence, Acute promyelocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, PROGNOSTIC-SIGNIFICANCE, Cumulative incidence, ATRA, Child, In Situ Hybridization, Fluorescence, Aged, 80 and over, relapse, PETHEMA, Incidence (epidemiology), ADDITIONAL CHROMOSOME-ABNORMALITIES, Age Factors, Hematology, Middle Aged, Prognosis, ARSENIC TRIOXIDE, FLT3 MUTATIONS, Leukemia, Treatment Outcome, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Female, Adult, medicine.medical_specialty, CYTOGENETIC CHANGES, Adolescent, Young Adult, 03 medical and health sciences, Internal medicine, Statistical significance, Complex Karyotype, medicine, Humans, Clinical significance, Aged, CONSOLIDATION THERAPY, Chromosome Aberrations, Chemotherapy, business.industry, medicine.disease, RISK-ADAPTED TREATMENT, TRANS-RETINOIC ACID, ATRA, Acute promyelocytic leukemia, chemotherapy, complex karyotype, prognostic, relapse, business, prognostic, 030215 immunology
Abstract

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with

Published
2019

38. LYMFOREST‐25: PERSONALLY‐TAILORED SURVIVAL PREDICTION OF PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA USING CLINICO‐GENOMIC PROGNOSTIC MODELS

Author

Orgueira, A. Mosquera, primary, López, M. Cid, additional, Raindo, A. Peleteiro, additional, Díaz Arias, J. Án., additional, Pérez, M. S. González, additional, Rodríguez, B. Antelo, additional, Pérez, L. Bao, additional, Ferro, R. Ferreiro, additional, Santos, C. Aliste, additional, Encinas, M. M. Pérez, additional, Rodríguez, M. F. Fraga, additional, Xu‐Monette, Z., additional, Visco, C., additional, Young, K., additional, and López, J. L. Bello, additional

Published
2021
Full Text
View/download PDF

39. 2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments

Author

Pérez-Encinas M, Lozano-Blázquez A, García-Pellicer J, Torre-Lloveras I, Poveda-Andrés JL, and Calleja-Hernández MÁ

Subjects
Service portfolio, Care activities, Research, education, Hospital pharmacy department, Survey, humanities, Education
Abstract

To report on the results obtained from the 2019 SEFH National Survey regarding the service portfolio, care activities, training programs and research work of Spanish hospital pharmacy departments.

Published
2021

41. STUDY OF THE MECHANISMS OF THROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS

Author

Agula, S., Cuenca-Zamora, E., Lis, M. J., Noya-Pereira, M. S., Gutierrez-Garcia, V, Garcia-Hernandez, M. C., Perez-Lopez, R., Fernandez, M. J., Palomera, L. R., Orti, G., Rosell, A., Vallansot, R., Angona-Figueras, A., Xicoy, B., Conesa, V, Puerta, J. M., Perez-Encinas, M., Cortes, M., Hernandez-Boluda, J. C., Carreno, G., Mora, E., Giraldo, P., Vicente, V., Steegman, J. L., and Ferrer-Marin, F.

Published
2021

42. Table 1. Clinical-biological and molecular characteristics of CML patients in each group evaluated

Author

Agula, S., Cuenca-Zamora, E., Lis, M. J., Noya-Pereira, M. S., Gutierrez-Garcia, V, Garcia-Hernandez, M. C., Perez-Lopez, R., Fernandez, M. J., Palom-Era, L. R., Orti, G., Rosell, A., Vallansot, R., Angona-Figueras, A., Xicoy, B., Conesa, V, Puerta, J. M., Perez-Encinas, M., Cortes, M., Hernandez-Boluda, J. C., Carreno, G., Mora, E., Giraldo, P., Vicente, V., Steegman, J. L., and Ferrer-Marin, F.

Published
2021

43. Evolving treatment patterns and outcomes in older patients (>= 60 years) with AML: changing everything to change nothing?

Author

Martinez-Cuadron D, Serrano J, Gil C, Tormo M, Martinez-Sanchez P, Perez-Simon J, Garcia-Boyero R, Rodriguez-Medina C, Lopez-Pavia M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Colorado M, Sayas M, Algarra L, Vidriales M, Rodriguez-Macias G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Ramos F, Rodriguez-Gutierrez J, Costilla-Barriga L, Labrador J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Sanz M, and Montesinos P

Abstract

There are no studies analyzing how therapeutic changes impact on outcomes of older AML patients. This study analyzes patient ' s and disease characteristics, treatment patterns, and outcomes of 3637 AML patients aged >= 60 years reported to the PETHEMA registry. Study periods were 1999-2006 (before hypomethylating agents-HMAs availability) vs 2007-2013, and treatments were intensive chemotherapy (IC), non-intensive, clinical trial (CT), and supportive care only (SC). Median age was 72 (range, 60-99), 57% male, median ECOG 1 (range, 0-4), secondary AML 914 (30%), with adverse-risk genetic in 720 (32%). Treatment differed between study periods (1999-2006 vs 2007-2013): IC 58% vs 32%, non-intensive 1 vs 23%, CT 0 vs 2%, SC 27 vs 28% (p < 0.001). Median OS was 4.7 months (1-year OS 29% and 5-years 7%, without differences between periods), 1.2 for SC, 7.8 for non-intensive, 8.6 for IC, and 10.4 for CT (p < 0.001). OS improved in the 2007-2013 period for IC patients (10.3 vs 7.5 months,p = 0.004), but worsened for SC patients (1.2 vs 1.6 months,p = 0.03). Our real-life study shows that, despite evolving treatment for elderly patients during the last decade, OS has remained unchanged. Epidemiologic registries will critically assess whether novel therapies lead to noteworthy advances in the near future (#NCT02606825).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results